drugset / Trial / NCT03883802
Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
Phase 2
Unknown
100 enrolled
WntResearch AB
BioVica AB · collabInstitut Català d'Oncologia · collabSAGA diagnostics AB · collabSMS-Oncology BV · collabUnilabs A/S · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Phase II study investigating the safety, tolerability and effect on disease reccurence of Foxy-5 as neo-adjuvant therapy in resected colon cancer patients treated with FOLFOX chemotherapy regimen. It is a two-arm study and patients will be randomised to receive either standard therapy (surgery + FOLFOX 6 months regimen) or standard therapy + neo-adjuvant administration of Foxy-5 prior to- and following surgery (maximum of 39 administrations) until initiation of FOLFOX therapy.
Timeline
- Start
- 2019-04-12
- Primary completion
- 2024-12-14
- Completion
- 2024-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Foxy-5 | Peptide | — | Intravenous |